Canadian pharmacies dispensed more than $2.4 billion worth of GLP-1 medications in the first six months of 2026, a pace that eclipses the full-year total for 2023 and signals the weight-loss and diabetes drug boom is far from peaking. The surge — driven by Novo Nordisk’s Ozempic and Wegovy alongside Eli Lilly’s Mounjaro and Zepbound — underscores a structural shift in pharmaceutical demand that is rippling through supply chains, retail margins and cross-border trade flows.
Ozempic maintains dominance as generics enter the fray
Ozempic remains the undisputed market leader, generating $1.49 billion in retail sales between January and June. Its sister drug Wegovy added $455 million, while Eli Lilly’s dual-therapy franchise — Mounjaro for diabetes and Zepbound for weight management — contributed $311 million and $124 million respectively. The figures, compiled by IQVIA Canada and inclusive of pharmacy mark-ups and dispensing fees, reveal a market expanding at a clip that would push annualised sales toward $4.8 billion. That would comfortably surpass the $3.9 billion recorded in 2025.
The first half also marked the debut of generic semaglutide in Canada, following a regulatory green light earlier this year. Apotex, the Toronto-based generic manufacturer, captured $15 million in sales before the June 30 cutoff. Dr. Reddy’s Laboratories, the Indian drugmaker, managed just $1 million after disclosing in July that facility issues would constrain supply until late 2026. Analysts caution that the generic segment’s contribution remains negligible for now, but the entry of lower-cost alternatives could reshape payer dynamics and pharmacy economics over the next 18 months.
Supply chains tested as demand outpaces forecasting
The velocity of growth has strained distribution networks on both sides of the border. Canadian wholesalers have leaned heavily on U.S. manufacturing sites — particularly Eli Lilly’s Indiana complex and Novo Nordisk’s fill-finish operations in North Carolina — to keep shelves stocked. Any disruption at those facilities, whether from regulatory action, raw-material shortages or labour disputes, would be felt acutely in Toronto, Montreal and Vancouver within weeks.
Pharmacy operators, meanwhile, are navigating a delicate margin environment. Dispensing fees on high-volume GLP-1 scripts provide steady revenue, but the drugs’ high acquisition costs tie up working capital and expose retailers to inventory obsolescence risk if prescribing patterns shift. Several independent chains have renegotiated payment terms with distributors to extend float, a trend that mirrors developments in the U.S. Midwest.
Cross-border implications for North American trade
The GLP-1 surge is quietly becoming a factor in Canada-U.S. pharmaceutical trade discussions. With both Novo Nordisk and Eli Lilly expanding U.S. production capacity — Lilly alone has committed more than $9 billion to new sites since 2023 — the security of supply for the Canadian market is increasingly tied to American industrial policy. Ottawa’s recent talks with Washington on critical mineral and biomanufacturing resilience have begun to reference active pharmaceutical ingredients for metabolic therapies, a category that barely registered two years ago.
Currency effects add another layer. A weaker Canadian dollar inflates the landed cost of imported finished goods, squeezing provincial formulary budgets that are already grappling with the drugs’ eligibility criteria. Some provinces have tightened reimbursement rules for weight-loss indications, directing patients toward diabetes diagnoses where clinical guidelines are more established. That friction between clinical demand and fiscal sustainability is likely to intensify if the $4.8 billion trajectory holds.
Why it Matters
The GLP-1 phenomenon has graduated from a clinical breakthrough to a macroeconomic force in Canada, reshaping pharmacy economics, stress-testing North American supply chains and inserting itself into bilateral trade conversations. If the current pace persists, the category will soon rival the entire Canadian generic drug market in annual value — a milestone that will force regulators, payers and manufacturers to confront hard questions about affordability, domestic manufacturing capacity and the long-term sustainability of a therapeutic class that shows no sign of slowing down.
